Gossamer Bio (NASDAQ:GOSS) Stock Picked Up by Analysts at Chardan Capital

Chardan Capital started coverage on shares of Gossamer Bio (NASDAQ:GOSS) in a research report issued to clients and investors on Tuesday, Briefing.com reports. The firm set a “buy” rating and a $160.00 price target on the stock.

A number of other analysts also recently issued reports on GOSS. Wall Street Zen downgraded shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Weiss Ratings raised shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. HC Wainwright reiterated a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Finally, Leerink Partners raised shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price objective for the company in a research report on Tuesday, July 28th. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Gossamer Bio presently has an average rating of “Hold” and an average price target of $240.00.

Gossamer Bio Stock Performance

GOSS opened at $9.28 on Tuesday. The company’s 50 day simple moving average is $12.34 and its 200 day simple moving average is $17.38. Gossamer Bio has a 1 year low of $8.99 and a 1 year high of $309.60. The stock has a market capitalization of $56.70 million, a PE ratio of -0.17 and a beta of 2.21.

Hedge Funds Weigh In On Gossamer Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Corient Private Wealth LP grew its stake in shares of Gossamer Bio by 41.3% during the second quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock valued at $927,000 after acquiring an additional 1,647,315 shares in the last quarter. Hsbc Holdings PLC lifted its stake in shares of Gossamer Bio by 1,289.4% in the second quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock worth $267,000 after acquiring an additional 1,469,175 shares in the last quarter. Bank of America Corp DE acquired a new position in shares of Gossamer Bio in the second quarter worth about $65,000. Hhlr Advisors LTD. acquired a new position in shares of Gossamer Bio in the second quarter worth about $819,000. Finally, ARCH Venture Management LLC purchased a new position in Gossamer Bio in the second quarter valued at about $1,326,004. 81.23% of the stock is owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with disorders involving the immune system, inflammation and fibrosis. The company is headquartered in San Diego, California, and primarily operates through the development of its proprietary drug candidates and strategic collaborations.

Gossamer’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary vascular remodeling.